CA Stock MarketDetailed Quotes
NGEN NervGen Pharma Corp
- 2.690
- -0.050-1.82%
15min DelayMarket Closed Jun 28 16:00 ET
188.11MMarket Cap-7911P/E (TTM)
2.850High2.510Low129.91KVolume2.710Open2.740Pre Close348.48KTurnover3.98052wk High0.24%Turnover Ratio69.93MShares1.58052wk Low-0.34EPS TTM148.26MFloat Cap3.980Historical HighLossP/E (Static)55.12MShs Float0.800Historical Low-0.38EPS LYR12.41%Amplitude--Dividend TTM10.00P/B1Lot Size--Div YieldTTM
About NervGen Pharma Corp Company
NervGen Pharma Corp principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291, and NVG-300.
Company Profile
SymbolNGEN
Company NameNervGen Pharma Corp
Founded2017
MarketTSX
Employees18
Fiscal Year Ends12-31
Address112-970 Burrard Street Unit 1290
CityVancouver
CountryCAN
Zip CodeV6Z 2R4
Phone+1 778 731-1711
Websitehttps://www.nervgen.com
Company Executives
- Name
- Position
- Salary
- Michael Kelly
- Director, President and Chief Executive Officer
- --
- Dr. Daniel D. Mikol, M.D.
- Chief Medical Officer
- --
- William J. Adams
- Chief Financial Officer and Corporate Secretary
- --
- Dr. Adam H. Rogers, M.D.
- Director
- --
- Krista L. McKerracher
- Independent Director
- --
- John Craig Thompson
- Independent Director
- --
- Dr. Randall E. Kaye,M.D.
- Independent Director
- --
- Brian Eric Bayley
- Independent Director
- --
- Glenn A. Ives
- Independent Director
- --
- Gianni Ruffolo
- Independent Director
- --
- Dr. Harold M. Punnett
- Independent Director
- --
Heat List
CA
Overall
Symbol
Latest Price
%Chg